Literature DB >> 8901614

Amphipathic domains in the C terminus of the transmembrane protein (gp41) permeabilize HIV-1 virions: a molecular mechanism underlying natural endogenous reverse transcription.

H Zhang1, G Dornadula, P Alur, M A Laughlin, R J Pomerantz.   

Abstract

Reverse transcription of HIV-1, without detergent or amphipathic peptide-induced permeability of the viral envelope, has been demonstrated to occur in the intact HIV-1 virion. In this report, we demonstrate that the amphipathic domains in the C terminus of the transmembrane glycoprotein (gp41) account for the natural permeability of the HIV-1 envelope to deoxyribonucleoside triphosphates, the substrates for DNA polymerization. In addition, nonphysiological deoxyribonucleoside triphosphates, such as 3'-azido-3'-deoxythymidine 5'-triphosphate and 3'-deoxythymidine 5'-triphosphate, can also penetrate the viral envelope, incorporate into, and irreversibly terminate reverse transcripts. As a result, viral infectivity is potently inhibited. Since the lentiviral envelope with these newly demonstrated characteristics can serve as a delivery pathway for anti-reverse transcription agents, we propose a unique strategy to prevent HIV-1 interand, possibly, intrahost transmission.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8901614      PMCID: PMC38024          DOI: 10.1073/pnas.93.22.12519

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  Kinetics of inhibition of endogenous human immunodeficiency virus type 1 reverse transcription by 2',3'-dideoxynucleoside 5'-triphosphate, tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepin-2(1H)-thion e, and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.

Authors:  Z Debyser; A M Vandamme; R Pauwels; M Baba; J Desmyter; E De Clercq
Journal:  J Biol Chem       Date:  1992-06-15       Impact factor: 5.157

2.  Lipid composition and fluidity of the human immunodeficiency virus.

Authors:  R C Aloia; F C Jensen; C C Curtain; P W Mobley; L M Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

3.  Theoretically determined three-dimensional structures for amphipathic segments of the HIV-1 gp41 envelope protein.

Authors:  R M Venable; R W Pastor; B R Brooks; F W Carson
Journal:  AIDS Res Hum Retroviruses       Date:  1989-02       Impact factor: 2.205

4.  Role of the carboxy-terminal portion of the HIV-1 transmembrane protein in viral transmission and cytopathogenicity.

Authors:  S J Lee; W Hu; A G Fisher; D J Looney; V F Kao; H Mitsuya; L Ratner; F Wong-Staal
Journal:  AIDS Res Hum Retroviruses       Date:  1989-08       Impact factor: 2.205

5.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

6.  Site-directed mutagenesis by overlap extension using the polymerase chain reaction.

Authors:  S N Ho; H D Hunt; R M Horton; J K Pullen; L R Pease
Journal:  Gene       Date:  1989-04-15       Impact factor: 3.688

7.  The cytoplasmic domain of simian immunodeficiency virus transmembrane protein modulates infectivity.

Authors:  L Chakrabarti; M Emerman; P Tiollais; P Sonigo
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

8.  Antimicrobial activity of synthetic magainin peptides and several analogues.

Authors:  M Zasloff; B Martin; H C Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

9.  Significance of premature stop codons in env of simian immunodeficiency virus.

Authors:  T Kodama; D P Wooley; Y M Naidu; H W Kestler; M D Daniel; Y Li; R C Desrosiers
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

10.  Topogenic analysis of the human immunodeficiency virus type 1 envelope glycoprotein, gp160, in microsomal membranes.

Authors:  O K Haffar; D J Dowbenko; P W Berman
Journal:  J Cell Biol       Date:  1988-11       Impact factor: 10.539

View more
  21 in total

1.  Reversion of a human immunodeficiency virus type 1 matrix mutation affecting Gag membrane binding, endogenous reverse transcriptase activity, and virus infectivity.

Authors:  R E Kiernan; A Ono; E O Freed
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

2.  Cellular membrane-binding ability of the C-terminal cytoplasmic domain of human immunodeficiency virus type 1 envelope transmembrane protein gp41.

Authors:  S S Chen; S F Lee; C T Wang
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

3.  Development of a new methodology for screening of human immunodeficiency virus type 1 microbicides based on real-time PCR quantification.

Authors:  Renato S Aguiar; Luciana J Costa; Helena S Pereira; Rodrigo M Brindeiro; Amilcar Tanuri
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

4.  In vitro synthesis of long DNA products in reactions with HIV-RT and nucleocapsid protein.

Authors:  Reshma M Anthony; Jeffrey J Destefano
Journal:  J Mol Biol       Date:  2006-10-06       Impact factor: 5.469

5.  Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle.

Authors:  R E Kiernan; A Ono; G Englund; E O Freed
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

6.  The cytopathicity of a simian immunodeficiency virus Mne variant is determined by mutations in Gag and Env.

Authors:  J T Kimata; J Overbaugh
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

7.  Restoration of wild-type infectivity to human immunodeficiency virus type 1 strains lacking nef by intravirion reverse transcription.

Authors:  M Khan; M Garcia-Barrio; M D Powell
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

8.  Inhibitors of human immunodeficiency virus type 1 reverse transcriptase target distinct phases of early reverse transcription.

Authors:  C W Hooker; W B Lott; D Harrich
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

9.  Partial rescue of the Vif-negative phenotype of mutant human immunodeficiency virus type 1 strains from nonpermissive cells by intravirion reverse transcription.

Authors:  G Dornadula; S Yang; R J Pomerantz; H Zhang
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

10.  Roles of Gag and NCp7 in facilitating tRNA(Lys)(3) Annealing to viral RNA in human immunodeficiency virus type 1.

Authors:  Fei Guo; Jenan Saadatmand; Meijuan Niu; Lawrence Kleiman
Journal:  J Virol       Date:  2009-06-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.